Lunai Bioworks has completed a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding its central nervous system platform with complementary neurotherapeutic compounds and delivery technologies.
The acquired portfolio introduces two distinct CNS delivery approaches: a blood-brain barrier-crossing prodrug system and a nose-to-brain delivery pathway that bypasses the BBB via olfactory and trigeminal routes. Together, these technologies expand Lunai’s ability to develop both individual and combination therapies, support its AI-driven patient stratification strategy, enable potential 505(b)(2) regulatory pathways for reformulated or repurposed therapeutics, and strengthen the company’s biodefense and countermeasure programs. The acquired assets will be integrated into Lunai Bioworks IP, a wholly owned subsidiary.
The transaction addresses one of the most persistent challenges in neurological drug development: delivering therapeutic agents across the blood-brain barrier in sufficient concentrations to achieve meaningful clinical effect while minimizing systemic exposure. Lunai’s Augusta platform is designed to stratify patient populations based on underlying biological drivers rather than traditional disease classifications, and the integration of the new delivery technologies is expected to support the development of targeted therapeutic combinations matched to specific patient subgroups across neurological disease and acute toxic or environmental exposures. The combined approach is intended to improve the efficiency of candidate selection and development across programs targeting Alzheimer’s disease and other neurological indications.
The transaction was the principal action undertaken by the company to achieve compliance with the Nasdaq Stockholders’ Equity Rule, and the company has disclosed that following the merger and preferred stock issuance, it believes its stockholders’ equity exceeds the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). The company is awaiting the Nasdaq panel’s formal determination of compliance, with no assurance that the panel will determine that the conditions have been satisfied. CEO David Weinstein described the transaction as bringing together complementary CNS delivery approaches that address one of the most persistent challenges in neurological drug development.
The acquisition expands Lunai’s role in biodefense-related initiatives, including its Pathfinder program, by increasing capacity to evaluate and deploy CNS-targeted countermeasures that combine established pharmacological agents with alternative delivery approaches designed for rapid administration following chemical or environmental exposures.
KEY QUOTES:
“This transaction brings together complementary CNS delivery approaches that address one of the most persistent challenges in neurological drug development. By integrating these technologies with our existing platform, we are expanding our ability to develop and deliver targeted therapies, while also opening additional pathways for partnership, licensing, and non-dilutive funding.”
David Weinstein, Chief Executive Officer, Lunai Bioworks
